https://orcid.org/0000-0002-6406-0243
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Objective: The aim of this research was to develop a questionnaire to facilitate choice of the most appropriate contraceptive method for individual women.
Methods: A literature review was conducted to identify key aspects influencing contraceptive choice and inform development of a questionnaire for online completion. Questionnaire development was overseen by a steering committee consisting of eight gynaecologists from across Europe. The initial draft underwent conceptual validation through cognitive debriefing interviews with six native English-speaking women. A qualitative content analysis was conducted to accurately identify potential issues and areas for questionnaire improvement. A revised version of the questionnaire then underwent face-to-face and online evaluation by 115 international gynaecologists/obstetricians with expertise in contraception, prior to development of a final version.
Results: The final conceptually validated Contraception: HeLping for wOmen’s choicE (CHLOE) questionnaire takes ≤10 min to complete and includes three sections to elicit general information about the individual, the health conditions that might influence contraceptive choice, and the woman’s needs and preferences that might influence contraceptive choice. The questionnaire captures the core aspects of personalisation, efficacy and safety, identified as key attributes influencing contraceptive choice, and consists of 24 closed-ended questions for online completion prior to a health care provider (HCP) consultation. The HCP receives a summary of the responses.
Conclusion: The CHLOE questionnaire has been developed to help women choose the contraception that best suits their needs and situation while optimising the HCP’s time.
Chinese abstract
目的：本研究的目的是研发一个问卷调查, 有助于不同女性选择最适合自己的避孕方法。
方法：通过一篇文献综述, 确定影响避孕选择的关键因素, 得知在线完成问卷的进展。问卷的研发是由来自欧洲各地的八位妇科学家组成的指导委员会监督。最初的草案进行概念验证是通过对六位以英语为母语的女性的进行面谈认知汇报。对问卷内容定性分析, 以准确地确定问卷潜在的问题和需要改进的地方。在问卷终版研发之前, 问卷的修订版由115位专业为避孕领域的国际妇产科专家进行面对面在线评估。
结果：最终的概念验证避孕法：帮助女性选择(CHLOE)问卷需要10分钟完成, 包括三个部分, 获取有关个人基本信息, 以及可能影响避孕选择的健康状况, 还有影响女性避孕选择的需要和偏好。问卷的核心在于获取个性化, 疗效和安全性, 确定影响避孕选择的关键因素, 包括24个在线完成的封闭式问题, 优于医护人员(HCP)咨询。HCP接收反应的汇总。
结论：CHLOE问卷已被开发, 帮助女性选择最适合自己需要和情况的避孕方法, 同时优化HCP的时间。
Acknowledgements
The authors would like to thank all the contraceptive counsellors who participated in the development of the CHLOE questionnaire. Medical writing assistance for the development of the manuscript was provided by Tracey Lonergan and Maite Artés (Adelphi) and supported by Teva. The CHLOE project was funded by Teva Pharmaceuticals Europe B.V.
Disclosure statement
C. J. is a consultant for Effik International, Gedeon Richter, MSD, Teva Pharmaceutical Industries and HRA Pharma. P. L. had a financial relationship (member of advisory boards, lecturer and/or consultant) with Bayer HealthCare Pharmaceuticals, Effik, MSD, Smith & Nephew, and Teva Pharmaceutical Industries. C. F. is member of the European scientific advisory board of Teva Pharmaceutical Industries and Exelgyn and has been a lecturer for Teva Pharmaceutical Industries, Bayer HealthCare Pharmaceuticals and Exelgyn. I. L. has a financial relationship (lecturer, member of advisory boards and/or consultant) with MSD, Teva Pharmaceutical Industries, Gedeon Richter, HRA Pharma and Nordic Pharma. R. E. N. has a financial relationship (lecturer, member of advisory boards and/or consultant) with Bayer HealthCare Pharmaceuticals, Endoceutics, Gedeon Richter, MSD, Novo Nordisk, Pfizer, Shionogi and Teva Pharmaceutical Industries. M. C. M. is a consultant for Teva Pharmaceutical Industries. A. F. -D. is a project manager for Adelphi. A. P. is a member of the European board of Teva Pharmaceutical Industries/Theramex without personal gain. N. C. -B. is a member of the European board of Teva Pharmaceutical Industries/Theramex without personal gain.
The CHLOE project was funded by Teva Pharmaceuticals Europe B.V., which also funded Adelphi for desk research analysis, cognitive interviews, and face-to-face and online evaluation, and Adelphi and Tracey Lonergan for medical writing and editorial support in manuscript development. The steering committee received personal compensation from Teva Pharmaceutical Industries for consulting, speaking and scientific support.